Overview

* Zynex ( ZYXI ) Q3 revenue fell 73% yr/yr, missing analyst expectations

* Company reported a Q3 net loss of $42.9 mln, impacted by asset impairment charges

Outlook

* Zynex ( ZYXI ) exploring strategic alternatives, including capital raising and restructuring

* Company enters 30-day grace period for $1.5 mln interest payment

Result Drivers

* TRICARE PAYMENT SUSPENSION - Revenue decline attributed to Tricare payment suspension and $2.8 mln revenue reduction during suspension period

* CLAIM SUBMISSION CHANGES - Changes to payer claim submissions and review practices led to denials and payment delays, impacting revenue

* WORKFORCE REDUCTIONS - Workforce reductions in early 2025 negatively impacted device orders, new patient onboarding, and revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $13.40 $23.02

Revenue mln mln (2

Analysts

)

Q3 EPS -$1.42

Q3 Net -$42.90

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Zynex Inc ( ZYXI ) is $2.85, about 80.1% above its November 14 closing price of $0.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)